Plasmid-borne extended-spectrum β-lactamase in a clinical isolate of Acinetobacter baumannii

References

1. Bergogne-Berezin, E. ( 2001;). The increasing role of Acinetobacter species as nosocomial pathogens. Curr Infect Dis Rep 3, 440–444.[CrossRef]
   [Google Scholar]
2. Bergogne-Berezin, E. & Towner, K. J. ( 1996;). Acinetobacter spp.as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9, 148–165.
   [Google Scholar]
3. Bouvet, P. J. M. & Grimont, P. A. D. ( 1987;). Identification and biotyping of clinical isolates of Acinetobacter. Ann Inst Pasteur Microbiol 138, 569–578.[CrossRef]
   [Google Scholar]
4. Dy, M. E., Nord, J. A., LaBombardi, V. J. & Kislak, J. W. ( 1999;). The emergence of resistant strains of Acinetobacter baumannii: clinical and infection control implications. Infect Control Hosp Epidemiol 20, 565–567.[CrossRef]
   [Google Scholar]
5. Jarlier, V., Nicolas, M. H., Fournier, G. & Philippon, A. ( 1988;). Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 10, 867–878.[CrossRef]
   [Google Scholar]
6. Joshi, S. G. ( 1998;). Assignment of antibiotic resistance to naturally occurring plasmids from clinical isolates of Acinetobacter species. PhD thesis, University of Pune, Pune, India.
7. Joshi, S. G., Litake, G. M., Niphadkar, K. B. & Ghole, V. S. ( 2003;). Multidrug resistant Acinetobacter baumannii isolates from a teaching hospital. J Infect Chemother 9, 187–190.[CrossRef]
   [Google Scholar]
8. Levin, A. S., Levy, C. E., Manrique, A. E. I., Medeiros, E. A. S. & Costa, S. F. ( 2003;). Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 21, 58–62.[CrossRef]
   [Google Scholar]
9. Mulvey, M. R., Soule, G., Boyd, D., Demczuk, W. & Ahmed, R. ( 2003;). Characterization of the first extended-spectrum β-lactamase-producing Salmonella isolate identified in Canada.Multi-provincial Salmonella typhimurium Case Control Study Group. J Clin Microbiol 41, 460–462.[CrossRef]
   [Google Scholar]
10. NCCLS ( 1997;). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A4. Villanova, PA: National Committee for Clinical Laboratory Standards.
11. Perilli, M., Felici, A., Oratore, A., Cornaglia, G., Bonfiglio, G., Rossolini, G. M. & Amicosante, G. ( 1996;). Characterization of the chromosomal cephalosporinases produced by Acinetobacter lwoffii and Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother 40, 715–719.
    [Google Scholar]
12. Poirel, L., Karim, A., Mercat, A., Le Thomas, I., Vahaboglu, H., Richard, C. & Nordmann, P. ( 1999;). Extended-spectrum β-lactamase-producing strain of Acinetobacter baumannii isolated from a patient in France. J Antimicrob Chemother 43, 157–158.[CrossRef]
    [Google Scholar]
13. Sambrook, J., Fritsch, E. F. & Maniatis, T. ( 1989;). Molecular Cloning: a Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
14. Stanisich, V. A. ( 1988;). Identification and analysis of plasmids at the genetic level. Methods Microbiol 21, 11–48.
    [Google Scholar]
15. Vahaboglu, H., Coskunkan, F., Tansel, O. & 10 other authors ( 2001;). Clinical importance of extended-spectrum β-lactamase (PER-1-type)-producing Acinetobacter spp.and Pseudomonas aeruginosa strains. J Med Microbiol 50, 642–645.
    [Google Scholar]
16. Von Graevenitz, A. ( 1995;). Acinetobacter, Alcaligenes, Moraxella and other non-fermentative gram-negative bacteria. In Manual of Clinical Microbiology, pp. 520–532. Edited by P. J. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover & R. H. Yolken. Washington, DC: American Society of Microbiology.
17. Willets, N. ( 1988;). Conjugation. Methods Microbiol 21, 49–75.
    [Google Scholar]